TrialBone marrow transplantation2019

Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial.

Hee-Je Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.